tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Whalen HR et al. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime. 2017 Transplantation pmid:26950724
Colombo M et al. Influence of Drug Brittleness, Nanomilling Time, and Freeze-Drying on the Crystallinity of Poorly Water-Soluble Drugs and Its Implications for Solubility Enhancement. 2017 AAPS PharmSciTech pmid:28168626
Saliba F et al. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. 2017 Am. J. Transplant. pmid:28133906
de Fijter JW et al. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. 2017 Am. J. Transplant. pmid:28027625
Kabat-Koperska J et al. Birth defects in juvenile Wistar rats after exposure to immunosuppressive drugs during pregnancy. 2017 Histol. Histopathol. pmid:27097725
Elens L and Haufroid V Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22? 2017 Pharmacogenomics pmid:29095105
Ma X et al. Inhibition effect of tacrolimus and platelet-derived growth factor-BB on restenosis after vascular intimal injury. 2017 Biomed. Pharmacother. pmid:28633129
Zidan AS Taste-masked tacrolimus-phospholipid nanodispersions: dissolution enhancement, taste masking and reduced gastric complications. 2017 Pharm Dev Technol pmid:26811031
Ueno P et al. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. 2017 Transplantation pmid:27490418
Li Y et al. [Study on the Effect of Immunosuppressive Agent FK506 on Growth and Migration of Lung Cancer Cell]. 2017 Zhongguo Fei Ai Za Zhi pmid:28738959
Gu K et al. Atypical pneumonia due to human bocavirus in an immunocompromised patient. 2017 CMAJ pmid:28507089
Nakamura Y et al. Successful Treatment of Behçet's Disease Associated with Acute Myeloid Leukemia with Myelodysplasia-related Changes Using Azacitidine and Tacrolimus before Allogeneic Hematopoietic Stem Cell Transplantation. 2017 Intern. Med. pmid:28502936
Sanghavi K et al. Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. 2017 Pharmacogenomics J. pmid:26667830
Heemann U and Viklicky O Is trough level variability the new tool for identifying patients at risk for rejection after transplantation? 2017 Nephrol. Dial. Transplant. pmid:28186537
Undre N and Dickinson J Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants. 2017 BMJ Open pmid:28377389
Størset E et al. Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. 2017 Br J Clin Pharmacol pmid:28374426
Ericzon BG et al. Pharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudy. 2017 Clin Transplant pmid:28295581
Lawrance IC et al. Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. 2017 Clin. Gastroenterol. Hepatol. pmid:28286194
Morita M et al. The onset risk of carcinoma in patients continuing tacrolimus topical treatment for oral lichen planus: a case report. 2017 Odontology pmid:27368962
Smolders EJ et al. Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation? 2017 Int. J. Antimicrob. Agents pmid:28185946
Shimizu S et al. Reduction of FR900525 using an S-(2-aminoethyl) l-cysteine-resistant mutant. 2017 J. Biosci. Bioeng. pmid:28185832
Sakurai K et al. Efficacy of combination therapy with tacrolimus and mizoribine for cyclophosphamide-resistant ANCA-associated glomerulonephritis. 2017 Int J Rheum Dis pmid:28205382
Nishiya Y et al. A new efficient method of generating photoaffinity beads for drug target identification. 2017 Bioorg. Med. Chem. Lett. pmid:28108248
Chung BH et al. Suppressive Effect of 1α,25-Dihydroxyvitamin D3 on Th17-Immune Responses in Kidney Transplant Recipients With Tacrolimus-Based Immunosuppression. 2017 Transplantation pmid:28107277
Wungwattana M and Savic M Tacrolimus interaction with nafcillin resulting in significant decreases in tacrolimus concentrations: A case report. 2017 Transpl Infect Dis pmid:28067989
Ak K et al. Tacrolimus-Eluting Suture Inhibits Neointimal Hyperplasia: An Experimental In Vivo Study in Rats. 2017 Eur J Vasc Endovasc Surg pmid:28065442
Martín-Fernández M et al. Effects of Cyclosporine, Tacrolimus, and Rapamycin on Osteoblasts. 2017 Transplant. Proc. pmid:29149986
Ivulich S et al. Clinical Challenges of Tacrolimus for Maintenance Immunosuppression Post-Lung Transplantation. 2017 Transplant. Proc. pmid:29149976
Liberal R et al. Expert clinical management of autoimmune hepatitis in the real world. 2017 Aliment. Pharmacol. Ther. pmid:28004405
Nakamura K et al. AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts. 2017 Eur. J. Pharmacol. pmid:27993641
Khan SA et al. Improvement in baroreflex control of renal sympathetic nerve activity in obese Sprague Dawley rats following immunosuppression. 2017 Acta Physiol (Oxf) pmid:28456134
Gelens MACJ et al. No evidence for progressive deterioration in stimulated insulin secretion in renal transplant recipients after 12years tacrolimus exposure. 2017 J. Diabetes Complicat. pmid:28720321
Wan T et al. Dual roles of TPGS based microemulsion for tacrolimus: Enhancing the percutaneous delivery and anti-psoriatic efficacy. 2017 Int J Pharm pmid:28629978
Tremblay S and Alloway RR Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations. 2017 AAPS J pmid:28717926
Chen P et al. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients. 2017 J Clin Pharm Ther pmid:27885697
Zhang W et al. Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation. 2017 Transplantation pmid:28885495
Burbulla LF et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. 2017 Science pmid:28882997
Khan S et al. Tacrolimus-loaded nanostructured lipid carriers for oral delivery-in vivo bioavailability enhancement. 2016 Eur J Pharm Biopharm pmid:27793753
Rebora A Tacrolimus and oral lichen planus. Possible absorption after mucosal application? 2016 J Eur Acad Dermatol Venereol pmid:26372839
Wang N et al. Paclitaxel and Tacrolimus Coencapsulated Polymeric Micelles That Enhance the Therapeutic Effect of Drug-Resistant Ovarian Cancer. 2016 ACS Appl Mater Interfaces pmid:26809267
Gabriel D et al. Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis. 2016 J Control Release pmid:27639683
Yoo EC et al. Developmental changes of MPA exposure in children. 2016 Pediatr. Nephrol. pmid:26743220
Sommerer C et al. Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. 2016 Trials pmid:26888217
Tsuji T et al. Therapeutic approach to mite-induced intractable dermatitis using novel immunomodulator FTY720 ointment (fingolimod) in NC/Nga mice. 2016 Allergol Int pmid:26666476
Ren H et al. Phosphatase inhibition increases AQP2 accumulation in the rat IMCD apical plasma membrane. 2016 Am. J. Physiol. Renal Physiol. pmid:27488997
Tanriover B et al. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate. 2016 Clin J Am Soc Nephrol pmid:27364616
Tsuji H et al. Efficacy and Safety of Grapefruit Juice Intake Accompanying Tacrolimus Treatment in Connective Tissue Disease Patients. 2016 Intern. Med. pmid:27301503
Peng L et al. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy. 2016 J. Formos. Med. Assoc. pmid:26315481
Castagna L et al. Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. 2016 Bone Marrow Transplant. pmid:26595078
Taylor KM and Sparrow MP Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis. 2016 Aliment. Pharmacol. Ther. pmid:27040166